21 09, 2020

Pharma Industry Awards 2020

By |2021-10-14T10:17:33+00:00September 21st, 2020|General News|

We’re pleased to announce that MIAS Pharma Ltd has been shortlisted for Pharma Supplier of the Year in this years Pharma Industry awards. We look forward to a great evening and catching up with our peers and suppliers.Since launching in 2014, the Pharma Industry Awards has established itself as the benchmark for those demonstrating excellence in the pharma

24 09, 2019

Good Distribution Practice (GDP): Issue of Theft

By |2019-09-24T14:56:53+00:00September 24th, 2019|General News|

The wholesale distribution of medicinal products and active substances is an important activity. The quality and the integrity of medicinal products can be affected by a lack of adequate control. The quality, safety and efficacy of medicinal products depend on a whole range of different factors. The most important factors are that

19 09, 2019

Pharma giant tackling counterfeit drugs using blockchain

By |2021-08-01T14:55:41+00:00September 19th, 2019|Industry News|

MIAS PHARMA UPDATEFighting counterfeit drugs with blockchain technology… The Asia-Pacific pharmaceutical giant Zuellig pharma is using a blockchain platform by SAP to assist consumers identify the medicines place of origin. With 1 in 10 medicinal products that are used in developing countries deemed fake, there is a substantial need to eradicate counterfeit drugs that could

17 09, 2019

Brexit Preparedness Checklist – HPRA

By |2019-09-17T11:32:15+00:00September 17th, 2019|Industry News|

The Health Products Regulatory Authority (HPRA) have released a 'Brexit Preparedness' checklist. The checklist has been divided into four parts which include:  Supply Chain  Customs  Medicines Regulatory Compliance Medical Devices Supply Chain In relation to the supply of medicines and medical devices, companies are requested to: Map your supply chain to

30 08, 2019

Further guidance on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal

By |2019-08-30T12:13:20+00:00August 30th, 2019|Industry News|

The Medicines & Healthcare products Regulatory Agency (MHRA) have released further guidance on the regulation of medicines, medical devices and clinical trials if there is no Brexit deal. In relation to medicines: The transitional provision in legislation will ensure that all currently granted Centrally Authorised Products (CAPs) automatically become UK MAs on

21 08, 2019

Hard-Brexit: MHRA preparations and impact on clinical trials

By |2021-10-13T14:36:36+00:00August 21st, 2019|Industry News|

With the appointment of Boris Johnson as Prime Minister, it is likely that the United Kingdom (UK) may leave the European Union (EU) on the 31st of October 2019 and without a deal (“Hard Brexit”). Pharmaceutical authorities see challenges for pharmaceutical manufacturers in many areas, not only in terms of drug availability and

19 08, 2019

Safety: Top concern for drug importation proposal

By |2022-10-25T15:56:45+00:00August 19th, 2019|General News|

Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan”. The action plan would allow importation of certain prescription drugs from Canada and other countries. Importing drugs, whether from Canada or elsewhere in the world, poses a big

19 08, 2019

Safety is top concern for recent U.S. drug importation proposal

By |2021-10-13T14:36:55+00:00August 19th, 2019|General News|

Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan”. The action plan would allow importation of certain prescription drugs from Canada and other countries. Importing drugs, whether from Canada or elsewhere in the world, poses a big

15 08, 2019

What is considered GMP-compliant equipment design?

By |2019-08-15T10:11:08+00:00August 15th, 2019|General News|

A question that gets frequently asked is what GMP-compliant equipment design is or how a system has to be made up in order to be GMP compliant and suitable for the manufacturing of medicinal products / APIs. The short answer is: the system must be qualifiable. Since this require some clarification, here

11 07, 2019

New Regulatory Approach for Cannabis Products!

By |2022-10-18T15:30:42+00:00July 11th, 2019|General News|

Health Canada has proposed a regulatory pathway for a new class of cannabis products known as Cannabis Health Products (CHPs). On June 19, 2019, Health Canada started a consultation on potential market for CHPs that would not require a practitioner’s oversight. Health Canada are accepting comments until September 3, 2019. There is

Go to Top